Inhibrx Shares Slip as Firm Ups Debt Load to $500 Million

Investors pushed Inhibrx Biosciences shares down 4.4% to $87.22 following news that the clinical-stage firm has expanded its credit facility with Oxford Finance to $500 million. This move comes as the company seeks to secure its financial runway while preparing for critical clinical data readouts.

July 16, 2026, 05:48 PM 2,253 0

Inhibrx Shares Slip as Firm Ups Debt Load to $500 Million

The expansion adds $325 million to the company’s original $175 million loan agreement. To finalize the arrangement, Inhibrx issued warrants allowing lenders to purchase 21,457 shares of common stock at a strike price of $93.21 per share. Despite the immediate market dip, the stock maintains a 10% gain since the beginning of the year.

Chief Financial Officer Kelly Deck indicated the capital injection is intended to sustain momentum for the company's core precision-engineered immunotherapies, ozekibart and INBRX-106. The firm remains in a pivotal phase, positioning these assets for upcoming testing milestones.

When reusing this material a link to Money Talk is required.